FDA Orange Book
Is there a generic for Striverdi Respimat?
Striverdi Respimat contains olodaterol. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Striverdi Respimat (olodaterol). The Orange Book shows its last listed patent expires January 19, 2027.
Run it in Rivvi
Map Striverdi Respimat and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Striverdi Respimat products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| spray, metered, inhalation | EQ 0.0025MG BASE/INH | Marketed (Rx) | None | 0 | None |
NDA 203108, held by BOEHRINGER INGELHEIM PHARMACEUTICALS INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Striverdi Respimat patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 7727984 | January 19, 2027 | Drug substance | None | 203108 |
Striverdi Respimat NDC codes
Questions
Is there a generic for Striverdi Respimat?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Striverdi Respimat (olodaterol). The Orange Book shows its last listed patent expires January 19, 2027.
What is the generic name for Striverdi Respimat?
The active ingredient in Striverdi Respimat is olodaterol, per the FDA Orange Book.
When does the Striverdi Respimat patent expire?
The last patent listed for Striverdi Respimat in the Orange Book expires January 19, 2027. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.